Safety and efficacy pharmacogenomics in pediatric psychopharmacology

Christopher A. Wall, Catherine Oldenkamp, Cosima Swintak

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Historically, clinicians have had few resources beyond empiric tools derived from population-based treatment algorithms and patient/family interviews to inform the "best choice" for psychopharmacologic intervention. Previously unappreciated interindividual variance in activity of cytochrome P450 enzymatic activity can lead to abnormal metabolism of many psychotropics and poor outcomes. Fortunately, advances in our understanding and application of psychiatric pharmacogenomic information have the potential to improve the quality of medical care for children at the level of the individual prescription.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalPrimary Psychiatry
Volume17
Issue number5
StatePublished - May 1 2010

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Safety and efficacy pharmacogenomics in pediatric psychopharmacology'. Together they form a unique fingerprint.

Cite this